Kathleen McKeever

1.0k total citations
23 papers, 777 citations indexed

About

Kathleen McKeever is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Kathleen McKeever has authored 23 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 5 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kathleen McKeever's work include T-cell and B-cell Immunology (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Kathleen McKeever is often cited by papers focused on T-cell and B-cell Immunology (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Kathleen McKeever collaborates with scholars based in United States, Switzerland and United Kingdom. Kathleen McKeever's co-authors include Janet Clarke, David E. Allison, Kelly M. Flagella, Mark X. Sliwkowski, Noël Dybdal, Leonard G. Presta, Camellia Adams, Ronald Herbst, Kathy Howell and Stephan Blüml and has published in prestigious journals such as Cancer Research, Annals of the Rheumatic Diseases and Forest Ecology and Management.

In The Last Decade

Kathleen McKeever

23 papers receiving 731 citations

Peers

Countries citing papers authored by Kathleen McKeever

Since Specialization

Citations

This map shows the geographic impact of Kathleen McKeever's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen McKeever with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen McKeever more than expected).

Fields of papers citing papers by Kathleen McKeever

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen McKeever. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen McKeever. The network helps show where Kathleen McKeever may publish in the future.

Co-authorship network of co-authors of Kathleen McKeever

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen McKeever. A scholar is included among the top collaborators of Kathleen McKeever based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen McKeever. Kathleen McKeever is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prednisolone and rapamycin reduce the plasma cell gene signature and may improve AAV gene therapy in cynomolgus macaques 2023 ·Gene Therapy ·(unknown), Jessica A. Chichester, Lili Wang, Roberto Calcedo, Jenny A. Greig, (unknown), Margaret C. Wright, Julien Couthouis, Sunjay Sethi, Brian E. McIntosh, Kathleen McKeever, Samuel Wadsworth, James M. Wilson, Emil Kakkis, Barbara Sullivan	4
2	Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression 2022 ·Molecular Therapy — Methods & Clinical Development ·Lili Wang, Claude C. Warzecha, (unknown), Jessica A. Chichester, Peter Bell, Elizabeth L. Buza, Zhenning He, M. Betina Pampena, Julien Couthouis, Sunjay Sethi, Kathleen McKeever, Michael R. Betts, Emil Kakkis, James M. Wilson, Samuel Wadsworth, Barbara Sullivan	19
3	Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia 2021 ·The Journal of Clinical Pharmacology ·(unknown), Nathalie Gosselin, Julie Taylor, Mary Scott Roberts, Kathleen McKeever, Jack Shi	6
4	Using climatic and biophysical attributes to model the presence and severity of root disease across the U.S. Northern Rocky Mountains 2020 ·Forest Ecology and Management ·Zachary A. Holden, Alan Swanson, (unknown), (unknown), (unknown), Kathleen McKeever, (unknown), Erin L. Landguth	1
5	Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials 2018 ·Clinical Pharmacokinetics ·(unknown), Kathleen McKeever, Julie Taylor, Christine Haller, (unknown), Simon Jones, Jack Shi	19
6	Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring 2017 ·Reproductive Toxicology ·Simone M. Nicholson, Gianluca Carlesso, Lily Cheng, (unknown), Karma Dacosta, Joel R. Leininger, Kathleen McKeever, (unknown), Devon K. Taylor, Katie Streicher, (unknown), (unknown), Raffaella Faggioni, Ronald Herbst, Rakesh Dixit, Patricia C. Ryan	10
7	Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment 2017 ·mAbs ·Frank R. Brennan, Joy Cavagnaro, Kathleen McKeever, Patricia C. Ryan, Melissa M. Schutten, John L. Vahle, Gerhard F. Weinbauer, Estelle Marrer‐Berger, Lauren E. Black	48
8	Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study 2016 ·Arthritis Research & Therapy ·Elena Schiopu, Soumya Chatterjee, Vivien Hsu, Armando Flor, Daniel Cimbora, Kaushik Patra, Wenliang Yao, Jing Li, Katie Streicher, Kathleen McKeever, Barbara White, Eliezer Katz, Jörn Drappa, (unknown), Ronald Herbst	60
9	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials 2015 ·The Oncologist ·Aaron R. Hansen, Natalie Cook, M. Ricci, Albiruni R. Abdul Razak, Christophe Le Tourneau, Kathleen McKeever, Lorin Roskos, Rakesh Dixit, Lillian L. Siu, Mary Jane Hinrichs	11
10	Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety 2014 ·Toxicology and Applied Pharmacology ·Patricia C. Ryan, Matthew A. Sleeman, Marlon C. Rebelatto, Bing Wang, Hong Lü, Xiaohong Chen, Chi‐Yuan Wu, Mary Jane Hinrichs, Lorin Roskos, (unknown), Kathleen McKeever, Rakesh Dixit	14
11	B-cell targeted therapeutics in clinical development 2013 ·Arthritis Research & Therapy ·Stephan Blüml, Kathleen McKeever, Rachel Ettinger, Josef S Smolen, Ronald Herbst	85
12	Abstract 4424: Nonclinical safety evaluation of MEDI0639 (Anti-DLL4 Mab) to support first time In human: linking DLL4-notch signaling blockade to exaggerated pharmacology effects in cynomolgus monkeys. 2013 ·Cancer Research ·Patricia C. Ryan, Jiaqi Huang, Haifeng Bao, Song Cho, Philip Z. Brohawn, Peter Burke, Kim Lehmann, Fernanda Pilataxi, Yihong Yao, Kathleen McKeever, Rakesh Dixit	4
13	THU0005 Investigating the Plasma Cell Signature in Autoimmune Disease 2013 ·Annals of the Rheumatic Diseases ·Katie Streicher, Chris Morehouse, (unknown), Bhargavi Rajan, Fernanda Pilataxi, K. A. Lehmann, Philip Z. Brohawn, Brandon W. Higgs, Kathleen McKeever, Steven A. Greenberg, David Fiorentino, Laura K. Richman, Bahija Jallal, Ronald Herbst, Yang Yao, K. Ranade	2
14	Developmental Immunotoxicology Assessment of Rituximab in Cynomolgus Monkeys 2010 ·Toxicological Sciences ·(unknown), Kathleen McKeever, (unknown), Steve Eppler, Gerhard F. Weinbauer, Joseph C. Beyer	42
15	Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal models 2009 ·Expert Opinion on Drug Discovery ·Rakesh Dixit, Laurie Iciek, Kathleen McKeever, Patricia C. Ryan	9
16	Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab 2005 ·Cancer Immunology Immunotherapy ·Camellia Adams, David E. Allison, Kelly M. Flagella, Leonard G. Presta, Janet Clarke, Noël Dybdal, Kathleen McKeever, Mark X. Sliwkowski	241
17	Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis 2005 ·Journal of Immunotherapy ·Yulia Vugmeyster, Joseph C. Beyer, Kathy Howell, Dan Combs, Paul J. Fielder, Jihong Yang, Ferhan Qureshi, (unknown), (unknown), Wolfgang Dummer, Henry B. Lowman, Kathleen McKeever	60
18	The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation 2005 ·The Veterinary Journal ·Joseph A. Impellizeri, Kathy Howell, Kathleen McKeever, (unknown)	33
19	B‐cell subsets in blood and lymphoid organs in Macaca fascicularis 2004 ·Cytometry Part A ·Yulia Vugmeyster, Kathy Howell, (unknown), (unknown), (unknown), Kathleen McKeever	28
20	Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys 2003 ·International Immunopharmacology ·Yulia Vugmeyster, Kathy Howell, Kathleen McKeever, Daniel L. Combs, Eleanor Canova‐Davis	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact